** Drug developer Eton Pharmaceuticals' ETON.O shares rise 6.2% to $15.51 premarket
** Company says its experimental drug, ET-600, passed a bioequivalence study against an FDA-approved reference product with the same active ingredient for treatment of a rare condition called central diabetes insipidus $(CDI.NZ)$
** A bioequivalence study compares a generic test formulation with the original reference drug
** CDI is an uncommon problem in which the body can't properly balance fluid levels prompting to make large amounts of urine
** Eton Pharma plans to file FDA marketing application in April 2025
** As of last close, company's shares have more than tripled in the past 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。